Key result
Prophylactic nimodipine linked to ~127% higher odds of favorable neurological outcome in aneurysmal subarachnoid hemorrhage.
Why the study?
Oral nimodipine recommendations for aneurysmal subarachnoid hemorrhage are based on 1980s trials, warranting reevaluation given advances in aneurysm treatment and neuro-intensive care.
Does prophylactic oral nimodipine improve neurological function and reduce vasospasm/infarction in contemporary patients with aneurysmal subarachnoid hemorrhage?
Cohort (n=312)
No
Does prophylactic oral nimodipine improve neurological function and reduce vasospasm/infarction in contemporary patients with aneurysmal subarachnoid hemorrhage?
In a contemporary cohort, prophylactic oral nimodipine for at least 14 days significantly reduced angiographic vasospasm and delayed cerebral infarction, and improved functional outcomes at 3 months in patients with aneurysmal subarachnoid hemorrhage.
Supports nimodipine in contemporary aSAH; extends prior evidence via propensity-matched data.
Oral nimodipine is recommended as standard therapy for aneurysmal subarachnoid hemorrhage (aSAH) based on trials from the 1980s. Given major advances in aneurysm treatment and neuro-intensive care, its effectiveness in contemporary settings warrants reevaluation. We retrospectively analyzed consecutive patients with aSAH treated between 2015 and 2025. Clinical, radiological, and outcome data were extracted from medical records. Patients receiving prophylactic oral nimodipine (Nimo+) were compared with those who did not (Nimo−). Propensity score matching (PSM) was applied to balance baseline characteristics. Primary outcome was neurological function at discharge and at 3 months, assessed with the Glasgow Outcome Scale (GOS). Secondary outcomes included angiographic vasospasm, cerebral infarction, and mortality. Of the 312 patients eligible for inclusion in this study, 102 received oral nimodipine and 210 did not. After PSM, 102 patients were included per group with no differences in baseline characteristics. Nimodipine was associated with lower rates of angiographic vasospasm (43% vs 64%; p < 0.001) and delayed infarction (38% vs 58%; p = 0.008) and with better GOS score at discharge ( p = 0.047) and at 3 months ( p = 0.008). Mortality did not differ between the two groups. Subgroup analysis showed benefits in terms of angiographic vasospasm, infarction, and functional outcome among patients receiving nimodipine ≥ 14 days, whereas shorter administration only reduced angiographic vasospasm. In this contemporary propensity score-matched cohort, oral nimodipine therapy reduced vasospasm and delayed infarction and improved neurological outcome without having an impact on mortality. Sustained administration for at least 14 days appears to be crucial to achieve benefit, favoring full-course nimodipine therapy in aSAH management.
No takes yet. Share an insight, caveat, or question.
Hounchonou et al. (2026) conducted a cohort in Aneurysmal subarachnoid hemorrhage (aSAH) (n=312). Oral nimodipine vs. No oral nimodipine was evaluated on Favorable neurological outcome (Glasgow Outcome Scale ≥ 4) at 3 months (OR 2.27, 95% CI 1.23-4.16, p=0.008). Prophylactic oral nimodipine was associated with a significantly higher rate of favorable neurological outcome at 3 months (OR 2.27) compared to no nimodipine in patients with aneurysmal subarachnoid hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: